These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 9228546)
1. Physical and biological significance of peptide sequences mediating the interaction between high molecular weight kininogen and plasma prekallikrein. Colman RW; Lin Y; Yan WY; McCrae KR; Shenoy SS; Harris RB Immunopharmacology; 1997 Jun; 36(2-3):193-200. PubMed ID: 9228546 [TBL] [Abstract][Full Text] [Related]
2. Direct evidence for multifacial contacts between high molecular weight kininogen and plasma prekallikrein. Lin Y; Shenoy SS; Harris RB; Colman RW Biochemistry; 1996 Oct; 35(39):12945-9. PubMed ID: 8841140 [TBL] [Abstract][Full Text] [Related]
3. High molecular weight kininogen peptides inhibit the formation of kallikrein on endothelial cell surfaces and subsequent urokinase-dependent plasmin formation. Lin Y; Harris RB; Yan W; McCrae KR; Zhang H; Colman RW Blood; 1997 Jul; 90(2):690-7. PubMed ID: 9226169 [TBL] [Abstract][Full Text] [Related]
4. Fourier transform infrared (FT-IR) spectroscopic studies of peptide models for interaction of the binding regions of high molecular weight kininogen and prekallikrein. Lin Y; Li W; Wu J; Zhang H; Colman RW Thromb Res; 1998 Apr; 90(2):65-72. PubMed ID: 9684759 [TBL] [Abstract][Full Text] [Related]
5. Structures of factor XI and prekallikrein bound to domain 6 of high-molecular weight kininogen reveal alternate domain 6 conformations and exosites. Li C; Barroeta AB; Wong SS; Kim HJ; Pathak M; Dreveny I; Meijers JCM; Emsley J J Thromb Haemost; 2023 Sep; 21(9):2378-2389. PubMed ID: 37068593 [TBL] [Abstract][Full Text] [Related]
6. Conformational analysis of synthetic peptides encompassing the factor XI and prekallikrein overlapping binding domains of high molecular weight kininogen. You JL; Page JD; Scarsdale JN; Colman RW; Harris RB Peptides; 1993; 14(5):867-76. PubMed ID: 8284263 [TBL] [Abstract][Full Text] [Related]
7. Localization of the binding site on plasma kallikrein for high-molecular-weight kininogen to both apple 1 and apple 4 domains of the heavy chain. Page JD; You JL; Harris RB; Colman RW Arch Biochem Biophys; 1994 Oct; 314(1):159-64. PubMed ID: 7944388 [TBL] [Abstract][Full Text] [Related]
8. Assembly of high molecular weight kininogen and activation of prekallikrein on cell matrix. Motta G; Shariat-Madar Z; Mahdi F; Sampaio CA; Schmaier AH Thromb Haemost; 2001 Sep; 86(3):840-7. PubMed ID: 11583317 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of contact activation by a kininogen peptide (HKH20) derived from domain 5. Nakazawa Y; Joseph K; Kaplan AP Int Immunopharmacol; 2002 Dec; 2(13-14):1875-85. PubMed ID: 12494915 [TBL] [Abstract][Full Text] [Related]
11. The carboxyl terminus of bradykinin and amino terminus of the light chain of kininogens comprise an endothelial cell binding domain. Hasan AA; Cines DB; Zhang J; Schmaier AH J Biol Chem; 1994 Dec; 269(50):31822-30. PubMed ID: 7989355 [TBL] [Abstract][Full Text] [Related]
12. Calorimetric and spectroscopic examination of the solution phase structures of prekallikrein binding domain peptides of high molecular weight kininogen. You JL; Scarsdale JN; Harris RB J Protein Chem; 1991 Jun; 10(3):301-11. PubMed ID: 1910462 [TBL] [Abstract][Full Text] [Related]
13. Solution phase conformation studies of the prekallikrein binding domain of high molecular weight kininogen. Scarsdale JN; Harris RB J Protein Chem; 1990 Oct; 9(5):647-59. PubMed ID: 2085389 [TBL] [Abstract][Full Text] [Related]
14. Localization of distinct functional domains on prekallikrein for interaction with both high molecular weight kininogen and activated factor XII in a 28-kDa fragment (amino acids 141-371). Page JD; Colman RW J Biol Chem; 1991 May; 266(13):8143-8. PubMed ID: 1708772 [TBL] [Abstract][Full Text] [Related]
15. The relative priority of prekallikrein and factors XI/XIa assembly on cultured endothelial cells. Mahdi F; Shariat-Madar Z; Schmaier AH J Biol Chem; 2003 Nov; 278(45):43983-90. PubMed ID: 12944405 [TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibody to human high-molecular-weight kininogen recognizes its prekallikrein binding site and inhibits its coagulant activity. Reddigari SR; Kaplan AP Blood; 1989 Aug; 74(2):695-702. PubMed ID: 2752143 [TBL] [Abstract][Full Text] [Related]
17. Pathogenic mechanisms of bradykinin mediated diseases: dysregulation of an innate inflammatory pathway. Kaplan AP; Joseph K Adv Immunol; 2014; 121():41-89. PubMed ID: 24388213 [TBL] [Abstract][Full Text] [Related]
18. Factor XII-independent cleavage of high-molecular-weight kininogen by prekallikrein and inhibition by C1 inhibitor. Joseph K; Tholanikunnel BG; Kaplan AP J Allergy Clin Immunol; 2009 Jul; 124(1):143-9. PubMed ID: 19342086 [TBL] [Abstract][Full Text] [Related]
19. Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor. Colman RW; Pixley RA; Najamunnisa S; Yan W; Wang J; Mazar A; McCrae KR J Clin Invest; 1997 Sep; 100(6):1481-7. PubMed ID: 9294114 [TBL] [Abstract][Full Text] [Related]
20. High molecular weight kininogen regulates prekallikrein assembly and activation on endothelial cells: a novel mechanism for contact activation. Motta G; Rojkjaer R; Hasan AA; Cines DB; Schmaier AH Blood; 1998 Jan; 91(2):516-28. PubMed ID: 9427705 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]